PM517. Transition into overt psychosis in individuals at ultra-high risk for psychosis: possible roles of multi-dimensional schizotypy and basic symptoms

s | 87 the studied polymorphisms via the restriction fragment length polymorphism method. Clinical factors such as gender, age, duration of illness, and final medication dosage were noted as well. The researchers measured psychopathology biweekly, using the Positive and Negative Syndrome Scale (PANSS) fivefactor model scale (positive, negative, excitement, cognitive, and depressive). A mixed model regression approach (SAS Proc MIXED) was used to analyze the effects of genetic and clinical factors on PANSS performance after aripiprazole treatment. Results: We found that the A1/A1 (T/T) genotype of DRD2/ ANKK1 Taq1A (rs1800497) polymorphism predicted superior aripiprazole treatment response specifically for positive and excitement symptoms. Otherwise, the T/T and T/C genotype groups of 5-HT2A T102C (rs6313) polymorphism predicted superior aripiprazole treatment response specifically for negative symptoms. Furthermore, the C/C genotype of 5-HT1A C-1019G (rs6295) polymorphism predicted superior aripiprazole treatment response specifically for cognitive and depressive symptoms. Finally, the clinical factors including dosage of aripiprazole and duration of illness were found to influence PANSS performance upon aripiprazole treatment. Conclusions: Our study shows DRD2, 5-HT1A, and 5-HT2A gene polymorphisms and clinical factors modulate aripiprazole efficacy in different symptom dimensions of schizophrenia.